Dr. Reddy’s Laboratories Ltd ADR (RDY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) has a cash flow conversion efficiency ratio of 0.043x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.57 Billion) by net assets ($362.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dr. Reddy’s Laboratories Ltd ADR - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Dr. Reddy’s Laboratories Ltd ADR total liabilities for a breakdown of total debt and financial obligations.
Dr. Reddy’s Laboratories Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy’s Laboratories Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korea Aerospace Industries
KO:047810
|
-0.073x |
|
TMX Group Limited
TO:X
|
0.114x |
|
Industrivarden AB ser. C
ST:INDU-C
|
0.053x |
|
LPP S.A.
WAR:LPP
|
0.432x |
|
Kerry Group
IR:KRZ
|
0.052x |
|
TELECOM ITALIA ADR 1
F:TQIA
|
N/A |
|
Pinnacle West Capital Corp
NYSE:PNW
|
0.092x |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
-0.484x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see Dr. Reddy’s Laboratories Ltd ADR market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $337.17 Billion | $46.43 Billion | 0.138x | -14.97% |
| 2024-03-31 | $280.55 Billion | $45.43 Billion | 0.162x | -36.46% |
| 2023-03-31 | $230.99 Billion | $58.87 Billion | 0.255x | +72.76% |
| 2022-03-31 | $190.53 Billion | $28.11 Billion | 0.148x | -99.02% |
| 2021-03-31 | $2.37 Billion | $35.70 Billion | 15.083x | +3.55% |
| 2020-03-31 | $2.05 Billion | $29.84 Billion | 14.566x | +7014.23% |
| 2019-03-31 | $140.20 Billion | $28.70 Billion | 0.205x | +43.61% |
| 2018-03-31 | $126.46 Billion | $18.03 Billion | 0.143x | -17.80% |
| 2017-03-31 | $124.04 Billion | $21.51 Billion | 0.173x | -46.04% |
| 2016-03-31 | $128.34 Billion | $41.25 Billion | 0.321x | +42.90% |
| 2015-03-31 | $111.30 Billion | $25.03 Billion | 0.225x | +4.93% |
| 2014-03-31 | $90.80 Billion | $19.46 Billion | 0.214x | +1076.68% |
| 2013-03-31 | $731.04 Billion | $13.32 Billion | 0.018x | -93.52% |
| 2012-03-31 | $57.44 Billion | $16.15 Billion | 0.281x | +61.44% |
| 2011-03-31 | $45.99 Billion | $8.01 Billion | 0.174x | -43.49% |
| 2010-03-31 | $42.91 Billion | $13.23 Billion | 0.308x | +187.63% |
| 2009-03-31 | $42.05 Billion | $4.50 Billion | 0.107x | -17.63% |
| 2008-03-31 | $47.07 Billion | $6.12 Billion | 0.130x | -54.17% |
| 2007-03-31 | $41.69 Billion | $11.83 Billion | 0.284x | +283.73% |
| 2006-03-31 | $22.27 Billion | $1.65 Billion | 0.074x | -32.37% |
| 2005-03-31 | $20.95 Billion | $2.29 Billion | 0.109x | -42.46% |
| 2004-03-31 | $21.08 Billion | $4.01 Billion | 0.190x | -18.03% |
| 2003-03-31 | $18.78 Billion | $4.35 Billion | 0.232x | -22.97% |
| 2002-03-31 | $15.44 Billion | $4.65 Billion | 0.301x | +156.40% |
| 2001-03-31 | $5.24 Billion | $614.87 Million | 0.117x | -17.97% |
| 2000-03-31 | $99.87 Million | $14.29 Million | 0.143x | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more